NCT07195318: Fisetin LOW

Fisetin Supplementation for Healthy Aging

Recruiting now NA Last updated 20 November 2025

What this trial tests

NA trial testing Fisetin in Healthy in 120 participants. Currently enrolling.

Timeline

24 September 2025

Primary endpoint
31 October 2026

20 September 2035

Quick facts

Lead sponsor	Ove Andersen
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	24 September 2025
Primary completion	31 October 2026
Estimated completion	20 September 2035
Sites	1 location across Denmark

Drugs / interventions tested

• Fisetin — full drug profile →
• Placebo

Conditions studied

• Healthy — all drugs for Healthy →

Sponsor

Ove Andersen — full company profile →

Who can join

50 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.

The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Beneficial Effects of Fisetin, a Senotherapeutic Compound, in Women's Reproductive Health and Diseases: Evidence from In Vitro to Clinical Studies.
   El Sayed S, Saiyed D, Macri VI, Asamoah-Mensah A, et al · · 2026 · PMID 41683217 · DOI 10.3390/nu18030393
2. Mechanistic Analysis of Fisetin in Liver Diseases and Its Potential Therapeutic Application in IFALD-A Review of In Vitro and In Vivo Studies.
   Belka M, Stawny M, Masternak MM, Krajka-Kuźniak V. · · 2025 · PMID 41515219 · DOI 10.3390/nu18010102